A human cell is a Rube Goldberg machine like no other, full of biological chain reactions that make the difference between life and death. Understanding these delicate relationships and how they go ...
In 2006 immunologist and 2025 Nobel prize winner Shimon Sakaguchi co-wrote an article in Scientific American that now feels ...
Nobel laureate Shimon Sakaguchi reflects on the role of regulatory T cells in peripheral immune tolerance and how the cells ...
MIT and Harvard scientists have designed an advanced type of immune cell called a CAR-NK cell that can destroy cancer while ...
Pharmaceutical Technology on MSN
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.
The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body.
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseasesTransaction further ...
Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies ...
Researchers are gaining insights into how external factors like air pollutants, diet and medications, and even microbes in ...
High levels of so-called "T cells" that respond to the coronavirus could be sufficient to offer protection against infection, an English study said on Tuesday, adding to the evidence of the crucial ...
Britain on Thursday said it would partner with an Oxford-based firm to provide testing for the T cell response of coronavirus vaccine candidates to try to assess their immune responses.
Bristol Myers Squibb (BMS) has announced the acquisition of Orbital Therapeutics, a privately held biotech specializing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback